Early detection

Colorectal Cancer & High Risk Adenoma

A 90% sensitivity for Colorectal Cancer and 40% for High Risk Adenoma (HRA) in Average-Risk Adults is still insufficient! Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.A Today, one in three adults have not completed the recommended CRC screening even though colorectal cancer is curable if caught early. Our multi-omics test which adds our powerful and proprietary customeBiome platform will be a revolutionary milestone and change the CRC health outcome.

​

Screening

Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are developing the first ever screening test for Pancreatic ductal adenocarcinoma.

Checkpoint Inhibitors

Non-Small Cell Lung Cancer Treatment

Immunotherapy (IO) is the use of medicines to help a person’s own immune system to recognize and destroy cancer cells.  The immune system uses “checkpoint” proteins on immune cells, which act like switches that turn on/off the immune response. Drugs that target these checkpoints are called checkpoint inhibitors.  In addition to checkpoint  genes like PD-L1 gene expression, optimizing IO is critical as starting on IO and switching to a targeted therapy can lead to adverse events. Our customeBiome atlas enables actionable IO personalized medicine in NSCLC.

Assistant Professor Itai Sharon

Migal - Galilee Research Institute

Head of the Computational Microbiology group at Migal.His research focuses on molecular biology techniques along with advanced computational methods and data science approaches to generate and analyze metagenomics and other data. Currently, research in the lab is focused on human-associated microbes and plant-microbiome interactions.

Assistant Professor Elizabeth Half

MD, Rambam Medial Center 

A specialist in gastroenterology and hepatology, Director of the Early Detection and Cancer Prevention Unit at Rambam Medical Center, director of the Hereditary Cancer Clinic and the BRCA Carrier Clinic

​

​

​

​

Assistant Prof Jennifer McQuade,

MD Oncologist MD Anderson

Jennifer L. McQuade, MD, MS, MA is an Assistant Professor and Physician Scientist in Melanoma Medical Oncology. Her research focuses on how lifestyle factors influence melanoma biology and the anti-tumor immune response with the goal of developing novel strategies to improve outcomes in melanoma.

​

Nurit Tweezer-Zaks

 MD, MBA

Pharmaceutical Industry Innovation expert across all therapeutic areas, Senior director at a global pharma MNC (Sanofi), Chief Medical Officer and Business Development at MediCane, Venture Capitalist and Investments in the life Sciences ( aMoon)
Strong scientific, clinical, and commercial proficiency in Business Development Orientation